Ivermectinobservational2023

A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?

Future virology

confidence

Key findings

Editorial on controversy around ivermectin for COVID-19; no clinical/biological endpoints reported.

Sample size: Not applicable
Population: Not applicable (editorial)
Dosing: Not applicable
Duration: Not applicable
Route: Not applicable
Blinding: not_reported
Controls: not_reported
Drug class: antiparasitic

Full abstract

This editorial examines what has caused the evidence around ivermectin to be so controversial, provides a brief analysis of recently published evidence, and highlights why it is important to learn lessons from ivermectin for future re-purposed drugs.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.